Diabetes drugs headlined Eli Lilly’s 2015 results, with Humalog and Trulicity contributing mightily to the upward sales curve. Trulicity rattled the market owing to its once-a-week frequency of injection. Despite liver toxicity concerns, Lilly’s basal insulin, peglispro, outperformed Sanofi’s Lantus in A1C reduction. On the Alzheimer’s front, Lilly continues to stand by experimental treatment solanezumab, but with a shift to investigate if it can prevent early brain function changes. If solanezumab proves effective, it could prove a boon: It would represent the first disease-modifying treatment for Alzheimer’s. Lilly had a solid year on the approval front, with six new products — Portrazza, Cyramza, and Synjardy among them — receiving a thumbs-up from the FDA in 2015. As for the pipeline, Lilly received FDA breakthrough therapy designations for advanced soft-tissue sarcoma treatment olaratumab and abemaciclib, a CDK 4/6 inhibitor for advanced breast-cancer treatment.